Tapewire

Nasdaq · USD

SPRY

ARS Pharmaceuticals, Inc.

Export transactions ↓
Tapewire entity
883
SEC CIK
0001671858
Parsed reports
268

Last 12 months

Inside the activity.

0 purchase rows · 5 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202503
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202602
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
October 01, 2026 Filed Oct 5, 2026 20:24 UTC
Casale DonnDirector · President and CEO
GrantStock Option (right to buy) · Derivative 1,036,923 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0002135296-26-000009 · form4-10052026_081042.xml · derivative · entry 1

Casale Donn · CIK 0002135296 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,036,923

Underlying: Common Stock · 1,036,923 shares

Expires 2036-09-30

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years.

Read SEC document
September 01, 2026 Filed Sep 2, 2026 21:27 UTC
Smith Margaret EkinsChief Commercial Officer
GrantStock Option (right to buy) · Derivative 1,001,738 $0.00 Strike: $5.77 $0.00
Disclosure

SEC source: 0002149973-26-000004 · form4-09022026_090920.xml · derivative · entry 1

Smith Margaret Ekins · CIK 0002149973 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,001,738

Underlying: Common Stock · 1,001,738 shares

Expires 2036-08-31

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years.

Read SEC document
July 01, 2026 Filed Jul 2, 2026 20:30 UTC
Casale DonnPresident
GrantStock Option (right to buy) · Derivative 898,456 $0.00 Strike: $7.96 $0.00
Disclosure

SEC source: 0002135296-26-000007 · form4-07022026_040714.xml · derivative · entry 1

Casale Donn · CIK 0002135296 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 898,456

Underlying: Common Stock · 898,456 shares

Expires 2036-06-30

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on June 1, 2027, and the remaining shares will vest monthly thereafter over three years.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:52 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001231919-26-000704 · form4-06262026_080605.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:19 UTC
Dadoo RajeevDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001193125-26-285521 · ownership.xml · derivative · entry 1

Dadoo Rajeev · CIK 0001951685 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC
Shah PratikDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001580787-26-000004 · form4-06262026_040614.xml · derivative · entry 1

Shah Pratik · CIK 0001580787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001952533-26-000002 · form4-06262026_040612.xml · derivative · entry 1

Kelly Michael · CIK 0001952533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC
Islam SaqibDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001575408-26-000002 · form4-06262026_040610.xml · derivative · entry 1

Islam Saqib · CIK 0001575408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001357522-26-000005 · form4-06262026_040608.xml · derivative · entry 1

Thompson Peter A. · CIK 0001357522 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

F2 · ownership.direct: Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001268854-26-000002 · form4-06262026_040607.xml · derivative · entry 1

SAUNDERS BRENT L · CIK 0001268854 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001230051-26-000002 · form4-06262026_040604.xml · derivative · entry 1

SCHNEIDER PHILLIP M · CIK 0001230051 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:15 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $10.54 $0.00
Disclosure

SEC source: 0001551891-26-000002 · form4-06262026_040601.xml · derivative · entry 1

Shawver Laura · CIK 0001551891 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2036-06-23

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 12, 2026 Filed Jun 13, 2026 00:06 UTC
Karas EricChief Commercial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $1.50 $0.00
Disclosure

SEC source: 0001951287-26-000004 · form4-06132026_120610.xml · derivative · entry 3

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 519,588

Underlying: Common Stock · 25,000 shares

Expires 2032-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
June 12, 2026 Filed Jun 13, 2026 00:06 UTC
Karas EricChief Commercial Officer
SaleCommon Stock 25,000 $10.00 $250,000.00
Disclosure

SEC source: 0001951287-26-000004 · form4-06132026_120610.xml · nonDerivative · entry 2

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,176

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

Read SEC document
June 12, 2026 Filed Jun 13, 2026 00:06 UTC
Karas EricChief Commercial Officer
Exercise / conversionCommon Stock 25,000 $1.50 $37,500.00
Disclosure

SEC source: 0001951287-26-000004 · form4-06132026_120610.xml · nonDerivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025.

Read SEC document
June 12, 2026 Filed Jun 13, 2026 00:04 UTC
Fitzpatrick Alexander AChief Legal Officer
SaleCommon Stock 3,355 $10.00 $33,550.00
Disclosure

SEC source: 0001398595-26-000004 · form4-06132026_120640.xml · nonDerivative · entry 1

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,910

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F2 · balance_after: Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:26 UTC
Karas EricChief Commercial Officer
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001951287-26-000002 · form4-01052026_090126.xml · derivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:27 UTC
Scott Kathleen D.Chief Financial Officer
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001794284-26-000002 · form4-01052026_090134.xml · derivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:25 UTC
Fitzpatrick Alexander AChief Legal Officer
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001398595-26-000002 · form4-01052026_090101.xml · derivative · entry 1

Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:23 UTC
Dorsey BrianChief Operating Officer
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001380762-26-000002 · form4-01052026_090119.xml · derivative · entry 1

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:22 UTC
Chakma JustinChief Business Officer
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001951238-26-000003 · form4-01052026_090113.xml · derivative · entry 1

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:19 UTC
Lowenthal Richard EDirector · PRESIDENT AND CEO · 10% owner
GrantStock Option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001378550-26-000003 · form4-01052026_090159.xml · derivative · entry 2

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:19 UTC
Lowenthal Richard EDirector · PRESIDENT AND CEO · 10% owner
GrantStock option (right to buy) · Derivative 875,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001378550-26-000003 · form4-01052026_090159.xml · derivative · entry 1

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 875,000

Underlying: Common Stock · 875,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:20 UTC
Tanimoto SarinaCHIEF MEDICAL OFFICER · 10% owner
GrantStock Option (right to buy) · Derivative 875,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001951291-26-000002 · form4-01052026_090152.xml · derivative · entry 2

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 875,000

Underlying: Common Stock · 875,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
January 02, 2026 Filed Jan 5, 2026 21:20 UTC
Tanimoto SarinaCHIEF MEDICAL OFFICER · 10% owner
GrantStock option (right to buy) · Derivative 240,000 $0.00 Strike: $11.49 $0.00
Disclosure

SEC source: 0001951291-26-000002 · form4-01052026_090152.xml · derivative · entry 1

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock · 240,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.

Read SEC document
November 13, 2025 Filed Nov 14, 2025 23:43 UTC
Dorsey BrianChief Operating Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 21,828 $0.00 Strike: $0.64 $0.00
Disclosure

SEC source: 0001380762-25-000005 · form4-11142025_111134.xml · derivative · entry 3

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,828 shares

Expires 2028-11-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
November 13, 2025 Filed Nov 14, 2025 23:43 UTC
Dorsey BrianChief Operating Officer
SaleCommon Stock 21,828 $8.71 $190,049.85
Disclosure

SEC source: 0001380762-25-000005 · form4-11142025_111134.xml · nonDerivative · entry 2

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,789

F2 · price: The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
November 13, 2025 Filed Nov 14, 2025 23:43 UTC
Dorsey BrianChief Operating Officer
Exercise / conversionCommon Stock 21,828 $0.64 $13,969.92
Disclosure

SEC source: 0001380762-25-000005 · form4-11142025_111134.xml · nonDerivative · entry 1

Dorsey Brian · CIK 0001380762 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:42 UTC
Chakma JustinChief Business Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $0.84 $0.00
Disclosure

SEC source: 0001951238-25-000005 · form4-11142025_111150.xml · derivative · entry 4

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,047

Underlying: Common Stock · 30,000 shares

Expires 2029-07-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:42 UTC
Chakma JustinChief Business Officer
SaleCommon Stock 136,380 $8.86 $1,208,790.49
Disclosure

SEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 3

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:42 UTC
Chakma JustinChief Business Officer
SaleCommon Stock 30,000 $8.91 $267,357.00
Disclosure

SEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 2

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,380

F1 · price: The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:42 UTC
Chakma JustinChief Business Officer
Exercise / conversionCommon Stock 30,000 $0.84 $25,200.00
Disclosure

SEC source: 0001951238-25-000005 · form4-11142025_111150.xml · nonDerivative · entry 1

Chakma Justin · CIK 0001951238 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:41 UTC
Shah PratikDirector
GiftCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001580787-25-000004 · form4-11142025_111147.xml · nonDerivative · entry 2

Shah Pratik · CIK 0001580787 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011

Disclosed balance after: 4,474,554

F3 · kind: The transaction involved the transfer of shares to a charitable fund.

F2 · ownership.nature: The Reporting Person is the trustee of The Pratik Shah Living Trust dated June 15, 2011.

Read SEC document
November 12, 2025 Filed Nov 14, 2025 23:41 UTC
Shah PratikDirector
GiftCommon Stock 250,000 $0.00 $0.00
Disclosure

SEC source: 0001580787-25-000004 · form4-11142025_111147.xml · nonDerivative · entry 1

Shah Pratik · CIK 0001580787 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Pratik Shah Living Trust dated June 15, 2011

Disclosed balance after: 4,574,554

F1 · kind: The transaction involved the gift of shares to a trust in which the Reporting Person is not the trustee and the Reporting Person has no pecuniary interest over shares held in the trust.

F2 · ownership.nature: The Reporting Person is the trustee of The Pratik Shah Living Trust dated June 15, 2011.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:30 UTC
Scott Kathleen D.Chief Financial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 12,500 $0.00 Strike: $1.50 $0.00
Disclosure

SEC source: 0001415889-25-022760 · form4-08222025_040801.xml · derivative · entry 4

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 739,830

Underlying: Common Stock · 12,500 shares

Expires 2032-02-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Immediately exercisable.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:30 UTC
Scott Kathleen D.Chief Financial Officer
SaleCommon Stock 12,500 $15.00 $187,500.00
Disclosure

SEC source: 0001415889-25-022760 · form4-08222025_040801.xml · nonDerivative · entry 2

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,042

F2 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:30 UTC
Scott Kathleen D.Chief Financial Officer
Exercise / conversionCommon Stock 12,500 $1.50 $18,750.00
Disclosure

SEC source: 0001415889-25-022760 · form4-08222025_040801.xml · nonDerivative · entry 1

Scott Kathleen D. · CIK 0001794284 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.

Read SEC document
August 21, 2025 Filed Aug 22, 2025 20:30 UTC
Lowenthal Richard EDirector · PRESIDENT AND CEO · 10% owner
SaleCommon Stock 50,000 $14.49 $724,345.00
Disclosure

SEC source: 0001415889-25-022761 · form4-08222025_040804.xml · nonDerivative · entry 1

Lowenthal Richard E · CIK 0001378550 · Director · PRESIDENT AND CEO · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,196,494

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025.

F2 · price: The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

Read SEC document
August 20, 2025 Filed Aug 21, 2025 21:36 UTC
Tanimoto SarinaCHIEF MEDICAL OFFICER · 10% owner
SaleCommon Stock 37,656 $14.09 $530,625.76
Disclosure

SEC source: 0001415889-25-022638 · form4-08212025_090845.xml · nonDerivative · entry 2

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,247,447

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025.

F4 · price: The weighted average sale price for the transaction reported was $14.0914 and the range of prices were between $14.00 and $14.205. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

Read SEC document
August 19, 2025 Filed Aug 21, 2025 21:36 UTC
Tanimoto SarinaCHIEF MEDICAL OFFICER · 10% owner
SaleCommon Stock 12,344 $14.03 $173,129.54
Disclosure

SEC source: 0001415889-25-022638 · form4-08212025_090845.xml · nonDerivative · entry 1

Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner

10b5-1 filing: Plan reported

Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020

Disclosed balance after: 1,285,103

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025.

F2 · price: The weighted average sale price for the transaction reported was $14.0254 and the range of prices were between $14.00 and $14.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3 · ownership.nature: The Reporting Person is trustee of the trust.

Read SEC document
July 01, 2025 Filed Jul 3, 2025 20:21 UTC
Karas EricChief Commercial Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $1.50 $0.00
Disclosure

SEC source: 0001415889-25-019321 · form4-07032025_080720.xml · derivative · entry 3

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 544,588

Underlying: Common Stock · 15,000 shares

Expires 2032-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Immediately exercisable.

Read SEC document
July 01, 2025 Filed Jul 3, 2025 20:21 UTC
Karas EricChief Commercial Officer
SaleCommon Stock 15,000 $16.99 $254,860.50
Disclosure

SEC source: 0001415889-25-019321 · form4-07032025_080720.xml · nonDerivative · entry 2

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,315

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

F3 · price: The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Read SEC document
July 01, 2025 Filed Jul 3, 2025 20:21 UTC
Karas EricChief Commercial Officer
Exercise / conversionCommon Stock 15,000 $1.50 $22,500.00
Disclosure

SEC source: 0001415889-25-019321 · form4-07032025_080720.xml · nonDerivative · entry 1

Karas Eric · CIK 0001951287 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,315

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:42 UTC
Flynn James E10% owner
SaleClass A Common Stock 370,074 $18.46 $6,831,566.04
Disclosure

SEC source: 0001193805-25-000959 · e664668_4-arsp.xml · nonDerivative · entry 2

Flynn James E · CIK 0001352546 · 10% owner

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · 10% owner

Deerfield Mgmt III, L.P. · CIK 0001610540 · 10% owner

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · 10% owner

Deerfield Mgmt IV, L.P. · CIK 0001713467 · 10% owner

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Through Deerfield Private Design Fund IV, L.P.

Disclosed balance after: 4,887,254

F1 · price: The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.20 to $18.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

F2 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.

F3 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:42 UTC
Flynn James E10% owner
SaleClass A Common Stock 370,075 $18.46 $6,831,584.50
Disclosure

SEC source: 0001193805-25-000959 · e664668_4-arsp.xml · nonDerivative · entry 1

Flynn James E · CIK 0001352546 · 10% owner

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · 10% owner

Deerfield Mgmt III, L.P. · CIK 0001610540 · 10% owner

Deerfield Private Design Fund III, L.P. · CIK 0001603333 · 10% owner

Deerfield Mgmt IV, L.P. · CIK 0001713467 · 10% owner

Deerfield Private Design Fund IV, L.P. · CIK 0001680307 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Through Deerfield Private Design Fund III, L.P.

Disclosed balance after: 4,887,254

F1 · price: The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.20 to $18.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.

F2 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.

F3 · ownership.nature: In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 21:21 UTC
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $17.26 $0.00
Disclosure

SEC source: 0001415889-25-018406 · form4-06272025_090643.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's board of directors, subject to Dr. Peter Kolchinsky's continuous service to the Issuer through the applicable vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:43 UTC
Dadoo RajeevDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $17.26 $0.00
Disclosure

SEC source: 0000950170-25-090944 · ownership.xml · derivative · entry 1

Dadoo Rajeev · CIK 0001951685 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:30 UTC
Shah PratikDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $17.26 $0.00
Disclosure

SEC source: 0001415889-25-018386 · form4-06272025_040610.xml · derivative · entry 1

Shah Pratik · CIK 0001580787 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:30 UTC GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $17.26 $0.00
Disclosure

SEC source: 0001415889-25-018388 · form4-06272025_040614.xml · derivative · entry 1

Kelly Michael · CIK 0001952533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:30 UTC
Islam SaqibDirector
GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $17.26 $0.00
Disclosure

SEC source: 0001415889-25-018385 · form4-06272025_040608.xml · derivative · entry 1

Islam Saqib · CIK 0001575408 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.